ACTA1

AKTISCHICHT Group is a pioneer in active regenerative wound therapy, leveraging proprietary, patented know-how. The company entered the wound care market in 2021 with two groundbreaking products that combine active wound healing with antibacterial and anti-biofilm properties: AKTISCHICHT® ECM-mimetic Dermal Matrix AKTISCHICHT® powdered ECM-mimetic Matrix – specifically developed for the optimal management of cavity and tunneling wounds These innovations represent a major advancement in promoting accelerated and effective wound regeneration, including in infected wounds. Building on this expertise, AKTISCHICHT® is set to launch a next-generation Hemostatic Powder designed to control both minor and major bleeding episodes, while also providing anti-inflammatory and antibacterial benefits, further expanding the company’s portfolio of advanced wound care solutions. ADVANTAGES AND PROPERTIES OF AKTISCHICHT WOUND THERAPY PRODUCTS • Active Wound Therapy • Anti-Inflammatory Properties • Antibacterial and Anti-Biofilm Properties • Optimizing Moisture and PH of the Wound Bed • Biodegradable in Wound Bed • Biocompatible • Porous, Breathable and Moisture-vapour Permeable • 100% Transparent • Flexible and Adjustable to the Shape of the Wound Bed • Usable in All Phases of Wound Healing • Significant Reduction of the Wound Healing Time • Reduction of Scar Tissue Formation • Applicable on Exposed Tendons and Bones • Applicable on the Joints Without Restricting the Joint Movement • Painless Application and No Need to Change